TY - JOUR
T1 - Clinical trial spots for cancer patients by tumour type
T2 - The cancer trials portfolio at clinicaltrials.gov
AU - Prasad, Vinay
AU - Goldstein, Jeffery A.
PY - 2015
Y1 - 2015
N2 - Background Although participation in cancer clinical trials is low, little is known about the number of available clinical trials, and open spots for patients. Moreover, it is unclear what the relationship is between clinical trial openings and the incidence and mortality of cancer subtypes. Methodology We identified the number of phase I, phase II and phase III registered at clinicaltrials.gov by cancer (tumour) type. All counts were over the preceding 5 years (2008-2013). We compared these counts against the incidence and prevalence of disease reported by Surveillance, Epidemiology and End Results (SEER) database for 32 common cancers. Results From 2008 to 2013, 3879 phase I trials, 4982 phase II trials and 1379 phase III trials concerning a cancer subtype were registered in clinicaltrials.gov. These trials had a cumulative proposed recruitment of 203,396, 421,502 and 697,787 patients, respectively. Trial enrolment varied by tumour type, with both over and under-representation occurring. Conclusion Opportunities to enrol in clinical trials vary by phase and tumour type. Oncologists must remain committed to clinical trials.
AB - Background Although participation in cancer clinical trials is low, little is known about the number of available clinical trials, and open spots for patients. Moreover, it is unclear what the relationship is between clinical trial openings and the incidence and mortality of cancer subtypes. Methodology We identified the number of phase I, phase II and phase III registered at clinicaltrials.gov by cancer (tumour) type. All counts were over the preceding 5 years (2008-2013). We compared these counts against the incidence and prevalence of disease reported by Surveillance, Epidemiology and End Results (SEER) database for 32 common cancers. Results From 2008 to 2013, 3879 phase I trials, 4982 phase II trials and 1379 phase III trials concerning a cancer subtype were registered in clinicaltrials.gov. These trials had a cumulative proposed recruitment of 203,396, 421,502 and 697,787 patients, respectively. Trial enrolment varied by tumour type, with both over and under-representation occurring. Conclusion Opportunities to enrol in clinical trials vary by phase and tumour type. Oncologists must remain committed to clinical trials.
KW - Burden of disease
KW - Cancer clinical trials
KW - Cancer trials
KW - Cancer trials portfolio
KW - Clinicaltrials.gov
KW - Phase I, phase II and phase III
UR - http://www.scopus.com/inward/record.url?scp=84969833441&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969833441&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2015.07.045
DO - 10.1016/j.ejca.2015.07.045
M3 - Article
C2 - 26321010
AN - SCOPUS:84969833441
SN - 0959-8049
VL - 51
SP - 2718
EP - 2723
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 17
ER -